Industry analysts expect M&A activity in the biotech space to accelerate in the back half of 2021 – and that could drive the ETF highlighted… Read More »This Biotech ETF Is “Prime Hunting Ground” For Big Pharma Companies Looking For Takeover Targets
After a down year for M&A activity in the biotech industry, 2021 is expected to see greater deal volume – and the four biotechs highlighted… Read More »Bought Out Or Standalone, These 4 Potential Biotech Takeover Targets Are Attractive Picks
When it comes to the question of which biotech companies could be the next M&A targets, one analyst cited in today’s article says the “easy… Read More »The Next Biotechs To Be Bought Up
“I believe that with the evidence of yesterday’s mergers, specifically the astoundingly well-priced purchase of Immunomedics (IMMU) by Gilead, that this is an area that… Read More »What Does “Merger Monday” Mean For Biotech?